Bruker (NASDAQ:BRKR) Price Target Cut to $75.00 by Analysts at Wells Fargo & Company

Bruker (NASDAQ:BRKR) had its price target cut by Wells Fargo & Company from $78.00 to $75.00 in a report issued on Wednesday,Benzinga reports. They currently have an overweight rating on the medical research company’s stock.

A number of other research firms have also recently commented on BRKR. Barclays cut their price objective on Bruker from $75.00 to $69.00 and set an “overweight” rating for the company in a research report on Wednesday. TD Cowen cut their price objective on Bruker from $74.00 to $72.00 and set a “hold” rating for the company in a research report on Wednesday, August 7th. Citigroup cut their price objective on Bruker from $95.00 to $80.00 and set a “buy” rating for the company in a research report on Wednesday, July 10th. The Goldman Sachs Group cut their price objective on Bruker from $72.00 to $60.00 and set a “sell” rating for the company in a research report on Tuesday, July 9th. Finally, Wolfe Research cut Bruker from an “outperform” rating to a “peer perform” rating in a research report on Monday, September 30th. One analyst has rated the stock with a sell rating, four have given a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Bruker presently has a consensus rating of “Moderate Buy” and an average target price of $79.36.

Bruker Trading Down 4.6 %

Shares of NASDAQ:BRKR opened at $57.73 on Wednesday. Bruker has a 12-month low of $54.55 and a 12-month high of $94.86. The company has a market capitalization of $8.74 billion, a PE ratio of 27.75, a PEG ratio of 2.83 and a beta of 1.20. The business has a 50 day moving average of $63.64 and a two-hundred day moving average of $66.21. The company has a current ratio of 1.66, a quick ratio of 0.75 and a debt-to-equity ratio of 1.24.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). Bruker had a net margin of 9.41% and a return on equity of 21.52%. The company had revenue of $864.40 million during the quarter, compared to analyst estimates of $866.46 million. During the same period in the previous year, the firm posted $0.74 earnings per share. The company’s revenue was up 16.4% compared to the same quarter last year. As a group, analysts forecast that Bruker will post 2.39 EPS for the current year.

Hedge Funds Weigh In On Bruker

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. TD Asset Management Inc boosted its stake in Bruker by 7.4% during the first quarter. TD Asset Management Inc now owns 1,788,763 shares of the medical research company’s stock worth $168,036,000 after buying an additional 123,984 shares during the last quarter. Atria Investments Inc acquired a new position in Bruker during the first quarter worth $1,142,000. Point72 Asset Management L.P. acquired a new position in Bruker during the second quarter worth $36,472,000. Epoch Investment Partners Inc. boosted its stake in Bruker by 15.2% during the first quarter. Epoch Investment Partners Inc. now owns 466,865 shares of the medical research company’s stock worth $43,857,000 after buying an additional 61,429 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its stake in Bruker by 1,694.4% during the second quarter. Assenagon Asset Management S.A. now owns 202,733 shares of the medical research company’s stock worth $12,936,000 after buying an additional 191,435 shares during the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.